Literature DB >> 23063584

Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes.

Wilfried Posch1, Sylvain Cardinaud, Chiraz Hamimi, Adam Fletcher, Annelies Mühlbacher, Klaus Loacker, Paul Eichberger, Manfred P Dierich, Gianfranco Pancino, Cornelia Lass-Flörl, Arnaud Moris, Asier Saez-Cirion, Doris Wilflingseder.   

Abstract

BACKGROUND: Control of HIV is suggested to depend on potent effector functions of the virus-specific CD8(+) T-cell response. Antigen opsonization can modulate the capture of antigen, its presentation, and the priming of specific CD8(+) T-cell responses.
OBJECTIVE: We have previously shown that opsonization of retroviruses acts as an endogenous adjuvant for dendritic cell (DC)-mediated induction of specific cytotoxic T lymphocytes (CTLs). However, in some HIV-positive subjects, high levels of antibodies and low levels of complement fragments coat the HIV surface.
METHODS: Therefore we analyzed the effect of IgG opsonization on the antigen-presenting capacity of DCs by using CD8(+) T-cell proliferation assays after repeated prime boosting, by measuring the antiviral activity against HIV-infected autologous CD4(+) T cells, and by determining IFN-γ secretion from HIV-specific CTL clones.
RESULTS: We find that DCs exposed to IgG-opsonized HIV significantly decreased the HIV-specific CD8(+) T-cell response compared with the earlier described efficient CD8(+) T-cell activation induced by DCs loaded with complement-opsonized HIV. DCs exposed to HIV bearing high surface IgG levels after incubation in plasma from HIV-infected subjects acted as weak stimulators for HIV-specific CTL clones. In contrast, HIV opsonized with plasma from patients exhibiting high complement and low IgG deposition on the viral surface favored significantly higher activation of HIV-specific CD8(+) T-cell clones.
CONCLUSION: Our ex vivo and in vitro observations provide the first evidence that IgG opsonization of HIV is associated with a decreased CTL-stimulatory capacity of DCs.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063584      PMCID: PMC4834990          DOI: 10.1016/j.jaci.2012.08.025

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  47 in total

Review 1.  Cellular immune responses to HIV.

Authors:  A J McMichael; S L Rowland-Jones
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

Review 2.  The immune complex: possible ways of regulating the antibody response.

Authors:  B Heyman
Journal:  Immunol Today       Date:  1990-09

3.  HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.

Authors:  Olivier Lambotte; Faroudy Boufassa; Yoann Madec; Ahn Nguyen; Cécile Goujard; Laurence Meyer; Christine Rouzioux; Alain Venet; Jean-François Delfraissy
Journal:  Clin Infect Dis       Date:  2005-08-30       Impact factor: 9.079

Review 4.  HIV controllers: how do they tame the virus?

Authors:  Asier Sáez-Cirión; Gianfranco Pancino; Martine Sinet; Alain Venet; Olivier Lambotte
Journal:  Trends Immunol       Date:  2007-11-05       Impact factor: 16.687

5.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Cao; L Qin; L Zhang; J Safrit; D D Ho
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

6.  Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs.

Authors:  Zoltán Bánki; Wilfried Posch; Asim Ejaz; Verena Oberhauser; Suzanne Willey; Christoph Gassner; Heribert Stoiber; Ulf Dittmer; Manfred P Dierich; Kim J Hasenkrug; Doris Wilflingseder
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

7.  Immune complex-mediated antigen presentation induces tumor immunity.

Authors:  Khadija Rafiq; Amy Bergtold; Raphael Clynes
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

8.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

9.  Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.

Authors:  D C Montefiori; G Pantaleo; L M Fink; J T Zhou; J Y Zhou; M Bilska; G D Miralles; A S Fauci
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

Review 10.  Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade.

Authors:  Gordon J Freeman; E John Wherry; Rafi Ahmed; Arlene H Sharpe
Journal:  J Exp Med       Date:  2006-09-25       Impact factor: 14.307

View more
  14 in total

1.  Generation of Human Monocyte-derived Dendritic Cells from Whole Blood.

Authors:  Wilfried Posch; Cornelia Lass-Flörl; Doris Wilflingseder
Journal:  J Vis Exp       Date:  2016-12-24       Impact factor: 1.355

Review 2.  Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?

Authors:  A Saez-Cirion; B Jacquelin; F Barré-Sinoussi; M Müller-Trutwin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

3.  Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells.

Authors:  Wilfried Posch; Marion Steger; Ulla Knackmuss; Michael Blatzer; Hanna-Mari Baldauf; Wolfgang Doppler; Tommy E White; Paul Hörtnagl; Felipe Diaz-Griffero; Cornelia Lass-Flörl; Hubert Hackl; Arnaud Moris; Oliver T Keppler; Doris Wilflingseder
Journal:  PLoS Pathog       Date:  2015-06-29       Impact factor: 6.823

Review 4.  Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity.

Authors:  Lisa T C Vogelpoel; Dominique L P Baeten; Esther C de Jong; Jeroen den Dunnen
Journal:  Front Immunol       Date:  2015-02-24       Impact factor: 7.561

Review 5.  Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.

Authors:  Jennifer Lambour; Mar Naranjo-Gomez; Marc Piechaczyk; Mireia Pelegrin
Journal:  Emerg Microbes Infect       Date:  2016-08-17       Impact factor: 7.163

Review 6.  Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

7.  Fcγ Receptor Type I (CD64)-Mediated Impairment of the Capacity of Dendritic Cells to Activate Specific CD8 T Cells by IgG-opsonized Friend Virus.

Authors:  Zoltán Bánki; Roland Werner; Lydia Riepler; Annika Rössler; Brigitte Müllauer; Verena Hegen; Wibke Bayer; J Sjef Verbeek; Ulf Dittmer; Heribert Stoiber
Journal:  Viruses       Date:  2019-02-08       Impact factor: 5.048

8.  Co- but not Sequential Infection of DCs Boosts Their HIV-Specific CTL-Stimulatory Capacity.

Authors:  Manuela Schönfeld; Ulla Knackmuss; Parul Chandorkar; Paul Hörtnagl; Thomas John Hope; Arnaud Moris; Rosa Bellmann-Weiler; Cornelia Lass-Flörl; Wilfried Posch; Doris Wilflingseder
Journal:  Front Immunol       Date:  2019-05-24       Impact factor: 7.561

Review 9.  Friend retrovirus studies reveal complex interactions between intrinsic, innate and adaptive immunity.

Authors:  Ulf Dittmer; Kathrin Sutter; George Kassiotis; Gennadiy Zelinskyy; Zoltán Bánki; Heribert Stoiber; Mario L Santiago; Kim J Hasenkrug
Journal:  FEMS Microbiol Rev       Date:  2019-09-01       Impact factor: 16.408

10.  Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.

Authors:  Eliott Lafon; Gabriel Diem; Christina Witting; Viktoria Zaderer; Rosa Maria Bellmann-Weiler; Markus Reindl; Angelika Bauer; Andrea Griesmacher; Vilmos Fux; Gregor Hoermann; Carl Miller; August Zabernigg; Ewald Wöll; Doris Wilflingseder; Cornelia Lass-Flörl; Wilfried Posch
Journal:  Front Immunol       Date:  2021-06-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.